{
  "spec_version": "3",
  "endpoint": "decisions",
  "stock_code": "4587",
  "company_name": "ペプチドリーム",
  "content_lang": "ja",
  "meta_lang": "en",
  "canonical_url": "https://the-shashi.com/tse/4587/",
  "api_url": "/api/4587/decisions.json",
  "updated": "2026-08-05",
  "license": "© 2026 Yutaka Sugiura. All rights reserved.",
  "attribution": "The社史 (the-shashi.com) — https://the-shashi.com/tse/4587/",
  "count": 3,
  "description": "Index of this company's management decisions. One decision = one endpoint: follow api_url for the full dossier (background, the decision itself, outcome, quoted primary sources and references).",
  "decisions": [
    {
      "slug": "mothers-ipo-2013",
      "url": "/tse/4587/decisions/mothers-ipo-2013/",
      "api_url": "/api/4587/decisions/mothers-ipo-2013.json",
      "year": 2013,
      "month": 6,
      "type": "capital",
      "tags": [
        "cp-listing",
        "bm-model-shift",
        "st-tech"
      ],
      "title": "創業7年でのマザーズ上場と、製薬大手への技術提供を収益源とする研究開発受託モデルの確立",
      "subtitle": "自社で薬を売るか、大手に技術を渡すか——赤字が常のバイオ業界で、窪田規一社長はなぜ黒字の単独経営を組み立てたか",
      "status": "implemented",
      "status_label": "実施"
    },
    {
      "slug": "peptistar-jv-2017",
      "url": "/tse/4587/decisions/peptistar-jv-2017/",
      "api_url": "/api/4587/decisions/peptistar-jv-2017.json",
      "year": 2017,
      "month": 6,
      "type": "alliance",
      "tags": [
        "pf-vertical",
        "cp-crossholding",
        "st-capex"
      ],
      "title": "塩野義製薬・積水化学工業との合弁によるペプチスターの設立と原薬製造の内製化",
      "subtitle": "探索に特化してきた創薬受託は、なぜ製造という川下まで自ら抱え込んだか",
      "status": "implemented",
      "status_label": "実施"
    },
    {
      "slug": "pdrpharma-acquisition-2022",
      "url": "/tse/4587/decisions/pdrpharma-acquisition-2022/",
      "api_url": "/api/4587/decisions/pdrpharma-acquisition-2022.json",
      "year": 2022,
      "month": null,
      "type": "acquisition",
      "tags": [
        "pf-diversify-related",
        "bm-model-shift"
      ],
      "title": "富士フイルム富山化学からの放射性医薬品事業の取得とPDRファーマの連結子会社化",
      "subtitle": "受託と提携で伸びた創薬ベンチャーは、放射性医薬品の製造販売基盤をどう第二の柱に据えたか",
      "status": "implemented",
      "status_label": "実施"
    }
  ],
  "by_type": [
    {
      "key": "acquisition",
      "count": 1,
      "url": "/api/4587/decisions/by-type/acquisition.json"
    },
    {
      "key": "alliance",
      "count": 1,
      "url": "/api/4587/decisions/by-type/alliance.json"
    },
    {
      "key": "capital",
      "count": 1,
      "url": "/api/4587/decisions/by-type/capital.json"
    }
  ],
  "by_decade": [
    {
      "key": "2010s",
      "count": 2,
      "url": "/api/4587/decisions/by-decade/2010s.json"
    },
    {
      "key": "2020s",
      "count": 1,
      "url": "/api/4587/decisions/by-decade/2020s.json"
    }
  ]
}